Phase 2 Study of Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
Status:
Recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
This is a Phase 2, open-label, multi-center study to evaluate the efficacy and the
safety/tolerability of poziotinib in seven patient cohorts for up to 603 previously treated
and treatment-naïve NSCLC patients. Cohorts 3 and 4 were added with Amendment 1 and three
additional cohorts were added with Amendment 2 (Cohorts 5, 6 and 7).